Rat Deoxypyridinoline ELISA Kit

Name: Rat Deoxypyridinoline ELISA Kit
SKU: DEIA-BJ2099
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Serum, plasma, cell culture supernatants, body fluid and tissue homogenate

Species Reactivity

Rat

Detection Method

Sandwich ELISA

Intended Use

Rat Deoxypyridinoline ELISA Kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of the Deoxypyridinoline. This ELISA kit is for research use only, not for therapeutic or diagnostic applications.

Contents of Kit

1. MICROTITER PLATE: 96 wells
2. ENZYME CONJUGATE: 6.0 mL or 10 ml
3. STANDARD A-F: 1 vial each
4. SUBSTRATE A: 6 mL
5. SUBSTRATE B: 6 mL
6. STOP SOLUTION: 6 mL
7. WASH SOLUTION (100 x): 10 mL
8. BALANCE SOLUTION: 3 mL

Storage

All components of this kit are stable at 2-8°C until the kit's expiration date.

Detection Range

5-100 nmol/L

Sensitivity

1.0 nmol/L

Citations

Have you cited DEIA-BJ2099 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

The state of bone metabolism in patients with type 2 diabetes mellitus

PATHOLOGIA

Authors: Kryvenko, V., I; Borodavko, O., I

Abstract

The aim of this work is to investigate the state of bone metabolism status and its relationship with carbohydrate metabolism in patients with type 2 diabetes. Materials and methods. 94 patients were studied, among whom the 1st group -22 patients with osteoporosis (OP), the 2nd group -22 patients with type 2 diabetes mellitus (DM), the a d group -50 patients with combined course of these diseases. An ultrasound densitometry using the Omnisense 7000 ultrasound densitometer (BeamMed Ltd, Israel) was performed for all the patients. The state of bone tissue was determined by criteria of the WHO. The levels of osteocalcin (OC), parathyroid hormone (PTH), calcitonin in blood serum, the level of deoxypyridinoline (DPD) were determined in morning urine for all patients. In patients with type 2 DM the levels of C-peptide, insulin, glucose, HbA1c and HOMA index were studied. Results. It was revealed that patients of the 3rd group had significant decrease in OC level by 44 %, DPD by 24 %, PHT by 28 % (P < 0.05) in comparison to the patients of the 1st group. In 53 % of patients of the 3rd group the development of OP was characterized by decreased bone formation and increased bone resorption. The patients of the 3rd group had significantly higher levels of Hblc by 11.5 %, glucose by 25 %, HOMA index by 7.2 % (P < 0.05), while the level of OC and DPD were lower by 8.5 % and 17 %, (P < 0.05) respectively in comparison with patients of group 2. The levels of OC and DPD were significantly lower in patients with decompensation of type 2 diabetes, in comparison with compensated diabetes by -12 % and -17 %, respectively (P < 0.05). The level of HbA1c significantly influences the state of bone metabolism. With an increase in HbA1c of more than 7.5 %, the level of OC decreases by 12 %, and DPD by 17 % (P < 0.05). Conclusions. The results suggest that type 2 DM leads to slowdown of bone metabolism, as the 3rd group patients had significantly reduced levels of OK and DPD as compared to the patients of the 1st group. Poor glycemic control can be one of the factors that reduce the level of bone markers.

Increased expression of the receptor for activation of NF-kappa B and decreased runt-related transcription factor 2 expression in bone of rats with streptozotocin-induced diabetes

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Authors: Hie, Mamiko; Tsukamoto, Ikuyo

Abstract

Insulin-dependent diabetes mellitus (IDDM) is associated with an increased risk of osteopenia/osteoporosis in humans. The effects of IDDM on osteoblastogenesis and osteoclastogenesis were investigated using diabetic rats at 2 weeks after the streptozotocin (STZ) injection. The weight of the tibia and proximal tibia and the amount of hydroxyproline and calcium in the proximal tibia were significantly lower in diabetic rats than control rats. Markers of bone formation, alkaline phosphatase (ALP) activity and the number of osteoblasts in the proximal tibia and the serum osteocalcin level, were significantly lower. Markers of bone resorption, activity of tartrate-resistant acid phosphatase (TRAP) and cathepsin K and the number of osteoclasts in the proximal tibia and urinary excretion of deoxypyridinoline, were higher in diabetic rats than control rats. mRNA levels of receptor for activation of NF-kappa B (RANK), c-fos, c-jun. TRAP and cathepsin K were significantly increased in diabetic rats, although RANK ligand, osteoprotegerin, macrophage colony-stimulating factor and c-fms levels were similar to the control value. The decreased expression of ALP, osteoclacin and collagen mR.NA in diabetic rats was associated with decreases in the expression of Runx2, Dlx5 and osterix and an unaltered expression of bone morphogenic protein-2. The level of RANK protein increased and Runx2 protein decreased in diabetic rats. These changes in the bone of STZ-induced diabetic rats were reversed by insulin-treatment. These suggested that short-term IDDM induced upregulation of osteoclastogenesis with an increase in RANK and downregulation of osteoblastogenesis with a decrease in Runx2 in bone.